Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279475 | 1.00 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL2039820 | 1.00 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL8804033 | 1.00 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL9276567 | 1.00 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL9389745 | 0.94 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL8978234 | 0.91 | ADORA2B (0.41) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL2733652 | 0.91 | ADORA2B (0.42) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL9284660 | 0.90 | ADORA2B (0.40) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL9385319 | 0.84 | ADORA2B (0.41) | ADORA2BLMNASMN1; SMN2ADORA2AACHE | |
| SCHEMBL21708442 | 0.83 | ADORA2B (0.45) | ADORA2BLMNASMN1; SMN2ADORA2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310174-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | OP NANO CO., LTD. (TW) | 2018-04-25 | — | — | EP | claimed |
| WO-2016197012-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | ORIENT PHARMA INC. (US) | 2016-12-08 | — | — | WO | claimed |
| WO-2015120254-A1 | DISULFIRAM COMPOSITIONS AND TREATMENTS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2015-08-13 | — | — | WO | claimed |
| EP-4161522-A1 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | Merck Sharp & Dohme LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4076452-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-4051712-A1 | DOSING REGIMEN OF ANTI-CD27 ANTIBODIES FOR TREATMENT OF CANCER | Merck Sharp & Dohme LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021252316-A1 | GRANULAR COMPOSITION OF AN ERK INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| WO-2021126731-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126732-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126728-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002045652-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| EP-0708645-A1 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995024199-A2 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284646-A1 | ALKYNYL(HETERO)AROMATIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | ALK, BRAF, DSTYK | ADORA2B 2710/4885LMNA 2916/4885SMN1; SMN2 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.